Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 17,401–17,420 of 17,987 drug recalls

Drug Recall Completed Historical recordClass II

Levoxyl (levothyroxine sodium) tablets, USP 88 mcg, packaged in a) 100-count bottles (NDC 60793-853-01) and b) 1000-count bottles ( NDC 60793-853-10 ) Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620.

by Pfizer Inc.

Reason
Chemical contamination: emission of strong odor after package was opened..
Recall initiated
March 28, 2013
Reported by FDA
April 24, 2013
Distribution
Nationwide and PR

View recall →

Drug Recall Completed Historical recordClass II

Levoxyl (levothyroxine sodium) tablets, USP 75 mcg, packaged in a) 100-count bottles (NDC 60793-852-01) and b) 1000-count bottles ( NDC 60793-852-10 ) Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620.

by Pfizer Inc.

Reason
Chemical contamination: emission of strong odor after package was opened.
Recall initiated
March 28, 2013
Reported by FDA
April 24, 2013
Distribution
Nationwide and PR

View recall →

Drug Recall Completed Historical recordClass II

Levoxyl (levothyroxine sodium) tablets, USP 50 mcg, packaged in a) 100-count bottles (NDC 60793-851-01) and b) 1000-count bottles ( NDC 60793-851-10 ) Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620.

by Pfizer Inc.

Reason
Chemical contamination: emission of strong odor after package was opened.
Recall initiated
March 28, 2013
Reported by FDA
April 24, 2013
Distribution
Nationwide and PR

View recall →

Drug Recall Completed Historical recordClass II

Levoxyl (levothyroxine sodium) tablets, USP 25 mcg, packaged in a) 100-count bottles (NDC 60793-850-01) and b) 1000-count bottles ( NDC 60793-850-10 ) Rx only, Manufactured and Distributed by: King Pharmaceuticals, Inc., Bristol, TN 37620.

by Pfizer Inc.

Reason
Chemical contamination: emission of strong odor after package was opened..
Recall initiated
March 28, 2013
Reported by FDA
April 24, 2013
Distribution
Nationwide and PR

View recall →

Drug Recall Terminated Historical recordClass II

Children's Acetaminophen Oral Suspension, 650 mg/20.3 mL unit dose cup (NDC 68094-650-59), packaged in 30-count cups per shipper case (NDC 68094-650-62), Pkg. By: Precision Dose, Inc., S. Beloit, IL 61080.

by Precision Dose Inc.

Reason
Labeling: Not Elsewhere Classified: This unit dose product is being recalled because the product's name includes the word "Children's" which is misleading since the 650 mg dose of acetaminophen contained within it, is an adult dose.
Recall initiated
March 21, 2013
Reported by FDA
April 24, 2013
Distribution
Nationwide and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass II

Copaxone (glatiramer acetate injection), 20 mg/1 mL, packaged in 30 single use PRE-FILLED syringes and 33 Alcohol Preps (swabs) per box, Marketed by: TEVA Neuroscience, Inc., Kansas City, MO 64131; Distributed by: TEVA Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 68546-317-30

by Teva Pharmaceuticals USA, Inc.

Reason
Presence of Foreign Substance: Product is being recalled due to receiving an elevated number of patient complaints related to a visible presence of medical grade silicone oil essential to the functionality of the syringe and plunger stopper system.
Recall initiated
December 5, 2012
Reported by FDA
April 24, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

buPROPion Hydrochloride Extended-Release Tablets (XL) 300 mg, 30-count tablets per bottle, Rx only, Distributed by: Actavis South Atlantic LLC, Sunrise, FL 33325; Packaged by: American Health Packaging, Columbus, OH 43217; NDC 67767-142-30.

by Actavis South Atlantic LLC

Reason
Failed USP Dissolution Test Requirements: Out-of-specification dissolution results at the 8 hour stability testing point.
Recall initiated
March 22, 2013
Reported by FDA
April 24, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Cefdinir for Oral Suspension, 125 mg/5 mL, packaged in a) 60 mL bottle (NDC 0093-4136-64); b) 100 mL bottle (NDC 0093-4136-73), Rx only, Teva Pharmaceuticals USA, Sellersville, PA 18960.

by Teva Pharmaceuticals USA, Inc.

Reason
Defective Container: This recall is being carried out due to the potential for improperly sealed bottles.
Recall initiated
February 26, 2013
Reported by FDA
April 17, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

Jolessa (levonorgestrel/ethinyl estradiol) Tablets, 0.15 mg/0.03 mg, 91-count tablets per extended-cycle tablet dispenser packaged in 3 dispensers per carton, Rx only, Manufactured By: Barr Laboratories, Inc., Pomona, NY 10970; Manufactured For: Teva Pharmaceuticals USA, Sellersville, PA 18960, NDC 0555-9123-66.

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Tablet/Capsule Specifications: This recall is being carried out due to an out of specification result for appearance.
Recall initiated
March 12, 2013
Reported by FDA
April 17, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

Portia (levonorgestrel and ethinyl estradiol) Tablets, USP, 0.15 mg/0.03 mg, 28-count tablets (containing 21 pink tablets followed by 7 white tablets) per blister card packaged in 6 blister cards per carton, Rx only, Barr Laboratories, Inc., Pomona, NY 10970, NDC 0555-9020-58.

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Tablet/Capsule Specifications: This recall is being carried out due to an out of specification result for appearance.
Recall initiated
March 12, 2013
Reported by FDA
April 17, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

LISINOPRIL AND HYDROCHLOROTHIAZIDE TABLETS, USP, 20 mg/25 mg, 100 (NDC 60429-046-01) and 1,000 (NDC 60429-046-10) count bottles, Rx only, GSMS Inc., Camarillo, CA

by Gsms

Reason
Presence of Foreign Substance: Reports of gray smudges identified as minute stainless steel particulates were found in the recalled tablets by the manufacturer
Recall initiated
March 11, 2013
Reported by FDA
April 17, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

0.9% Sodium Chloride Injection, USP, 50 mL, Manufactured by Hospira, Inc., Lake Forest, IL 60045, NDC 0409-7984-36 Hospira, Inc., Lake Forest, IL 60045

by Hospira Inc.

Reason
Lack of Assurance of Sterility: The product is being recall due to the product lot being incorrectly released without meeting product specifications. There is the potential for the solution to leak from the administrative port to the fill tube seal.
Recall initiated
February 18, 2013
Reported by FDA
April 10, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Ethambutol Hydrochloride Tablets, USP, 100 mg, 100-count tablets per bottle, Rx only, Mfd. for: Versapharm Incorporated, Marietta, GA; Mfd. by: West-Ward Pharmaceutical Corp., Eatontown, NJ 07724; NDC 61748-011-01.

by West-Ward Pharmaceutical Corp.

Reason
Subpotent Drug: Out Of Specification results for assay at the stability time-point of 24 months.
Recall initiated
March 18, 2013
Reported by FDA
April 10, 2013
Distribution
Nationwide.

View recall →

Drug Recall Terminated Historical recordClass III

Fougera Ketoconazole Cream 2%, 15g tube, Rx only, Labeled with E. Fougera & Co., a division of Fougera Pharmaceuticals Inc., Melville, New York 11747, NDC 0168-0099-15

by Fougera Pharmaceuticals Inc.

Reason
Failed Impurities/Degradation Specifications: Ketoconazole Cream 2% is the subject of a voluntary drug recall by Fougera due to an Out Of Specification result for an unknown degradant product
Recall initiated
July 18, 2012
Reported by FDA
April 10, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

TEV-TROPIN (somatropin (rDNA origin) for injection) 5 mg (15 IU). Prescription Only. Distributed By: TEVA Biologics & Specialty Products Division of Teva Pharmaceuticals USA, Sellersville, PA 18960 Manufactured in Israel.

by Ferring Pharmaceuticals Inc

Reason
Labeling: Label Mix-up: Units of Lot 201131320087 are packaged in cartons labelled for Needle-Free Head B, but contaiin Needle-Free Head A
Recall initiated
February 1, 2013
Reported by FDA
April 10, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Amoxicillin for Oral Suspension, 125mg/5mL, a) 80 mL (NDC 43598-222-80); b) 100mL, (NDC 43598-222-52); c)150 mL (NDC 43598-222-53) bottles, Rx only, Dist. By: Dr. REDDY'S Laboratories, Inc., Bridgewater, NJ 08807

by Dr Reddys Laboratories Tennessee LLC

Reason
Microbial Contamination of Non-Sterile Products: Suspensions made from these lots of Amoxicillin 125 mg/5 mL showed yeast and mold growth at the 14 day time point.
Recall initiated
February 15, 2013
Reported by FDA
April 10, 2013
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass III

Tizanidine Tablets USP, 4 mg, 150-count tablets per bottle, Rx Only, Mfd. By: Dr. Reddy's Laboratories Limited, Bachepally - 500 090 India; NDC 55111-180-15.

by Dr. Reddy'S Laboratories

Reason
Labeling Illegible: There is a possibility that the bottle labels do not contain the strength of the product as well as other printing details.
Recall initiated
March 19, 2013
Reported by FDA
April 10, 2013
Distribution
Nationwide and Puerto Rico.

View recall →

Drug Recall Terminated Historical recordClass II

CLONAZEPAM ORALLY DISINTERGRATING Tablets, USP, 0.5 mg, 60 tablets (10 blister cards of 6 tablets each), TEVA PHARMACEUTICALS USA, Sellersville PA 18960, NDC #0555-0096-96

by Teva Pharmaceuticals USA, Inc.

Reason
Failed Content Uniformity Specifications: Recall is being carried out due to an out-of-specification result for content uniformity.
Recall initiated
February 7, 2013
Reported by FDA
April 10, 2013
Distribution
NC

View recall →

Drug Recall Terminated Historical recordClass II

Oxiracetam & Choline , Oxiracetam 460mg Choline 110mg capsules a) 30 count bottle, b) 60 count bottle, c) 90 count bottle, OTC, BoostYourGrade, LLC, Orlando, FL. 32826

by Palmer Natural Products

Reason
Marketed Without an Approved NDA/ANDA: The products are unapproved drugs
Recall initiated
March 11, 2013
Reported by FDA
April 10, 2013
Distribution
Florida, Idaho, California and Hong Kong. This product can be ordered on line.

View recall →

Drug Recall Terminated Historical recordClass II

BoostYourGrade.com, Piracetam 390mg Choline 104mg capsules, 250 count bottle, OYC, BoostYourGrade, LLC, Orlando, FL 32826

by Palmer Natural Products

Reason
Marketed Without an Approved NDA/ANDA: The products are unapproved drugs
Recall initiated
March 11, 2013
Reported by FDA
April 10, 2013
Distribution
Florida, Idaho, California and Hong Kong. This product can be ordered on line.

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.